A Phase II Trial of Fotemustine and Cisplatin in Central Nervous System Metastases from Non-small Cell Lung Cancer

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 69-71

  Cotto, C ^a   Berille, J ^e   Souquet, P J ^e   Riou, R ^b   Croisile, B ^e   Turjman, F ^c   Giroux, B ^e   Brune, J ^a   Trillet Lenoir, V ^d  

^a LOUIS PRADEL HOSPITAL   (France)

^b Respiratory Diseases Department   (France)

^c HÔPITAL NEUROLOGIQUE   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e NONE

Author keywords

Central nervous system metastases; Chemotherapy; Cisplatin; Fotemustine; Non small cell lung cancer

Indexed keywords

CISPLATIN; FOTEMUSTINE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SURVIVAL RATE;

EID: 0001318359     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00507-2     Document Type: Article

References (11)

1. Trillet V, Catajar JF, Croisile B, et al. Cerebral metastases as first symptom of bronchogenic carcinoma. Cancer 1991, 67, 2935-2940.
2. Le Chevallier T, Zabbe C, Gouva S, et al. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. Eur J Cancer Clin Oncol 1989, 25, 1651-1652.
3. Jacquillat C, Khayat D, Banzet P, et al. Final report of a french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66, 1873-1878.
4. Frenay M, Giroux B, Khoury S, et al. Phase II study of fotemustine in recurrent supra-tentorial malignant gliomas. Eur J Cancer 1991, 27, 852-856.
5. Kleisbauer JP, Guérin JC, Arnaud A, et al. Chimiothérapie par cisplatine à forte dose dans les métastases cérébrales des cancers du poumon. Bull Cancer 1990, 77, 661-665.
6. World Health Organization. WHO Handbook for Reporting the Results of Cancer Treatment. WHO offset publication no 48. Geneva, 1979.
7. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993, 342, 19-21.
8. Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981, 7, 1633-1638.
9. Pujol JL, Monnier A, Berille J, et al. Phase II study of nitrosourea fotemustine as a single-drug therapy in poor prognosis non-small-cell lung cancer. BrJ Cancer, in press.
10. Rivière A, Le Cesne A, Berille J, et al. Cisplatin-fotemustine combination in inoperable non-small-cell lung cancer: preliminary report of a French multicentre phase II trial. Eur J Cancer 1994, 30A, 587-590.
11. Rudd R, Allen R, Berille J, et al. Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer. Cancer Chemother Pharmacol 1994, 34, 444-446.